89Zr PET imaging guided validation of the medicinal potentiality of UiO-66 based nano drug delivery system
摘要
In this work, positron nuclide 89Zr was introduced to verify the medical feasibility of UiO-66 as a medical nanodrug carrier via positron emission tomography-computed tomography (PET–CT) imaging. A radiopharmaceutical nanodrug, DOX@89Zr-UiO-66-PEG-FA, was well constructed through subsequent doxorubicin (DOX) encapsulation and surface PEGylation of UiO-66 nanocarrier radiolabeled with 89Zr. Subsequently, tumoricidal effect of DOX@89Zr-UiO-66-PEG-FA in murine breast cancer (4T1) models had been evaluated. DOX@89Zr-UiO-66-PEG-FA has acceptable stability, excellent cargo loading rate (79.28%), pH-stimulated response property and high cancer cell binding affinity. As a result, PET–CT guided anticancer investigations reveal that DOX@89Zr-UiO-66-PEG-FA can well suppress tumor growth with satisfactory biosafety.
Graphic abstract